Everolimus and exemestane represent a standard treatment for metastatic hormone receptor-positive/HER2-negative advanced breast cancer resistant to aromatase inhibitors. CA 15-3 serum levels detect soluble forms of MUC-1, a transmembrane oncoprotein aberrantly overexpressed in breast cancers. In clinical practice, CA 15-3 may be used to indicate treatment failure in the absence of readily measurable disease during cytotoxic therapy. In the targeted therapy era, it is important to note that the C-terminal subunit of MUC-1 interacts with PI3K/AKT pathway, inducting cell growth. Vice versa, the block of this pathway may influence MUC-1 expression and CA 15-3 serum levels. In this report, we emphasize the equivocal role of CA 15-3 serum levels in monitoring treatment with everolimus, suggesting a potential and intriguing role of a CA 15-3 increase as paradox predictive biomarker of response to everolimus.

Orlandi, A., Di Dio, C., Calegari, M. A., Barone, C. A., Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: A change of paradigm in a case series, <<BIOMARKERS IN MEDICINE>>, 2016; 10 (11): 1191-1195. [doi:10.2217/bmm-2016-0142] [http://hdl.handle.net/10807/94413]

Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: A change of paradigm in a case series

Orlandi, Armando
;
Di Dio, Carmela
Secondo
;
Calegari, Maria Alessandra
Penultimo
;
Barone, Carlo Antonio
Ultimo
2016

Abstract

Everolimus and exemestane represent a standard treatment for metastatic hormone receptor-positive/HER2-negative advanced breast cancer resistant to aromatase inhibitors. CA 15-3 serum levels detect soluble forms of MUC-1, a transmembrane oncoprotein aberrantly overexpressed in breast cancers. In clinical practice, CA 15-3 may be used to indicate treatment failure in the absence of readily measurable disease during cytotoxic therapy. In the targeted therapy era, it is important to note that the C-terminal subunit of MUC-1 interacts with PI3K/AKT pathway, inducting cell growth. Vice versa, the block of this pathway may influence MUC-1 expression and CA 15-3 serum levels. In this report, we emphasize the equivocal role of CA 15-3 serum levels in monitoring treatment with everolimus, suggesting a potential and intriguing role of a CA 15-3 increase as paradox predictive biomarker of response to everolimus.
Inglese
Orlandi, A., Di Dio, C., Calegari, M. A., Barone, C. A., Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: A change of paradigm in a case series, <<BIOMARKERS IN MEDICINE>>, 2016; 10 (11): 1191-1195. [doi:10.2217/bmm-2016-0142] [http://hdl.handle.net/10807/94413]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/94413
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 2
social impact